Seattle-based ZymoGenetics has added $125 million to its cash reserves, bringing total cash on hand to about $400 million. Company execs say that much of the money will go to a late-stage trial of Thrombin, an experimental drug to control bleeding during surgery. The funds will also help bankroll the creation of a 50-man sales force that will be assembled to market Thrombin once it receives FDA approval.
- read this article in the Seattle Post-Intelligencer for more